Research programme: regenerative therapeutics - Kringle Pharma/Kyoto University
Alternative Names: Biomaterial assisted regenerative therapeutics - Kringle Pharma/Kyoto UniversityLatest Information Update: 03 Aug 2022
At a glance
- Originator Kringle Pharma; Kyoto University
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Unspecified